Compare Ginkgo Bioworks Holdings Inc (DNA) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs DexCom, Inc. — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while DexCom, Inc. trades at $84.11 (market cap $31.86B). The key difference: DexCom, Inc. is far larger — about 41.7× Ginkgo Bioworks Holdings Inc's market cap, and DexCom, Inc. is more actively traded (3,607,070 versus 3,204,177). Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and DexCom, Inc. for 62 Days on average.
| DNA | DXCM | |
|---|---|---|
Market Cap | $763.64M | $31.86B |
Volume | 3,204,177 | 3,607,070 |
Sector | Health | Health |
52-Week High | $15.83 | $92.34 |
52-Week Low | $5.48 | $54.84 |
Typical Hold Time | 7 Days | 62 Days |
Enterprise Value | $865.59M | $31.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day. The technical outlook is bullish based on moving averages, while oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with a negative net income margin of -219.6%. Recent news includes a partnership with TuneLab and a $17.5 million ARPA-H subcontract.
The outlook is challenged by persistent losses and negative cash flow, though strategic partnerships offer growth potential. Analyst sentiment is divided evenly between buy, hold, and sell ratings. Key risks include execution on profitability and high cash burn. The stock presents a speculative opportunity dependent on the company's ability to monetize its technology platform.
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
